• BioNxt published a press release on July 6, 2026, outlining progress in its sublingual semaglutide oral dissolvable film program for GLP-1 delivery.
• The company moved the project into the next development stage, with formulation optimization, analytical method work, and compatibility testing underway.
• BioNxt positioned the needle-free thin-film approach as a potential alternative to injectable GLP-1 therapies; the candidate remains unapproved.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioNxt Solutions Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202607060305ACCESSWRNAPR_____1186869) on July 06, 2026, and is solely responsible for the information contained therein.